Pipeline

GeneQuine’s development pipeline consists of several gene therapy product candidates for musculoskeletal disorders. All product candidates are helper-dependent adenoviral gene therapy vectors and are intended for local delivery.

GeneQuine is currently focusing on developing gene therapies for osteoarthritis and intervertebral disc degeneration.

Osteoarthritis:

Preclinical
Proof-of-Concept
IND-enabling
Studies
Clinical
Phase I
Clinical
Phase II
Clinical
Phase III
GQ-303
GQ-203/FX201 Acquired by Flexion Therapeutics, Inc.

Intervertebral Disc Degeneration:

Preclinical
Proof-of-Concept
IND-enabling
Studies
Clinical
Phase I
Clinical
Phase II
Clinical
Phase III
GQ-401